Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Hormone-receptor Positive Breast Cancer
Interventions: DRUG: exemestane and pazopanib
Sponsor: GlaxoSmithKline